Dyslipidaemia in HIV-1-infected patients receiving protease inhibitors after initial treatment with first-line-based non-nucleoside reverse transcriptase inhibitors: A cross-sectional study

BMJ Open

Volumn 2, Issue 4, 2012, Pages

  Pefura Yone, Eric Walter ^a,b   Kengne, André Pascal ^c   Ashuntantang, Gloria ^a,d   Betyoumin, Awa Foueudjeu ^e   Ngogang, Jeanne ^a,e  

^a UNIVERSITY OF YAOUNDÉ I   (Cameroon)

^b Yaounde Jamot Hospital   (Cameroon)

^c UNIVERSITY OF CAPE TOWN   (South Africa)

^d YAOUNDÉ GENERAL HOSPITAL   (Cameroon)

^e Department of Biochemistry   (Cameroon)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; CAMEROON; CROSS-SECTIONAL STUDY; DYSLIPIDEMIA; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MAJOR CLINICAL STUDY; MALE; TREATMENT DURATION; TREATMENT FAILURE;

EID: 84865135730     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2012-001317     Document Type: Article

References (27)

1. Grunfeld C. Dyslipidemia and its treatment in HIV infection. Top HIV Med 2010;18:112-18.
2. Troll JG. Approach to dyslipidemia, lipodystrophy, and cardiovascular risk in patients with HIV infection. Curr Atheroscler Rep 2011;13:51 -6.
3. Haubrich RH, Riddler SA, DiRienzo AG, et al. Metabolic outcomes in a randomized trial of nucleoside, nonnucleoside and protease inhibitor-sparing regimens for initial HIV treatment. AIDS 2009;23:1109-18.
4. Friis-Moller N, Sabin CA, Weber R, et al. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 2003;349:1993-2003.
5. Heath KV, Chan KJ, Singer J, et al . Incidence of morphological and lipid abnormalities: gender and treatment differentials after initiation of first antiretroviral therapy. Int J Epidemiol 2002;31:1016-20. (Pubitemid 35446877)
6. Feeney ER, Mallon PW. HIV and HAART-associated dyslipidemia. Open Cardiovasc Med J 2011;5:49-63.
7. Domingos H, Cunha RV, Paniago AM, et al. Metabolic effects associated to the highly active antiretroviral therapy (HAART) in AIDS patients. Braz J Infect Dis 2009;13:130-6.
8. Palella FJ Jr., Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV outpatient study investigators. N Engl J Med 1998;338:853-60. (Pubitemid 28135961)
9. Gsponer T, Petersen M, Egger M, et al. The causal effect of switching to second-line ART in programmes without access to routine viral load monitoring. AIDS 2012;26:57-65.
10. von Wyl V, Yerly S, Boni J, et al. Incidence of hiv-1 drug resistance among antiretroviral treatment-naive individuals starting modern therapy combinations. Clin Infect Dis 2012;54:131-40.
11. Organisation Mondiale de la Santé. Recommandations rapides: Traitement antirétroviral de l'infection à VIH chez l'adulte et l'adolescent 2010. http://www.who.int/hiv/pub/arv/rapid-advice-art-fr.pdf (accessed 12 Dec 2011).
12. Ministère de la Santé Publique du Cameroun. Directives nationales de prise en charge par les antirétroviraux des personnes (adultes et adolescents) infectés par le VIH. Yaoundé 2010.
13. Pefura Yone EW, Kengne AP, Kuaban C. Incidence, time and determinants of tuberculosis treatment default in Yaounde, Cameroon: a retrospective hospital register-based cohort study. BMJ Open 2011;1:e000289.
14. World Health Organization. Antiretroviral therapy for HIV infection in adults and adolescents in resource-limited settings: towards universal access. 2006 revision http://www.who.int/hiv/pub/arv/adult/fr/index.html (accessed 10 Oct 2010).
15. Chesney MA, Ickovics JR, Chambers DB, et al. Self-reported adherence to antiretroviral medications among participants in HIV clinical trials: the AACTG adherence instruments. Patient care committee & adherence working group of the outcomes committee of the Adult Aids Clinical Trials Group (AACTG). AIDS Care 2000;12:255-66. (Pubitemid 30426745)
16. National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report. Circulation 2002;106:3143-421.
17. Zannou DM, Denoeud L, Lacombe K, et al. Incidence of lipodystrophy and metabolic disorders in patients starting non-nucleoside reverse transcriptase inhibitors in benin. Antivir Ther 2009;14:371-80.
18. Lake JE, Currier JS. Switching antiretroviral therapy to minimize metabolic complications. HIV Ther 2010;4:693-711.
19. Pefura Yone EW, Betyoumin AF, Kengne AP, et al. First-line antiretroviral therapy and dyslipidemia in people living with HIV-1 in Cameroon: a cross-sectional study. AIDS Res Ther 2011;8:33.
20. Buchacz K, Weidle PJ, Moore D, et al. Changes in lipid profile over 24 months among adults on first-line highly active antiretroviral therapy in the home-based AIDS care program in rural Uganda. J Acquir Immune Defic Syndr 2008;47:304 -11.
21. Padmapriyadarsini C, Ramesh Kumar S, Terrin N, et al. Dyslipidemia among HIV-infected patients with tuberculosis taking once-daily nonnucleoside reverse-transcriptase inhibitor-based antiretroviral therapy in India. Clin Infect Dis 2011;52:540-6.
22. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the national cholesterol education program adult treatment panel iii guidelines. J Am Coll Cardiol 2004;44:720-32.
23. Oka F, Naito T, Oike M, et al. Correlation between HIV disease and lipid metabolism in antiretroviral-naive HIV-infected patients in Japan. J Infect Chemother 2011;18:17-21.
24. Constans J, Pellegrin JL, Peuchant E, et al. Plasma lipids in HIV-infected patients: a prospective study in 95 patients. Eur J Clin Invest 1994;24:416- 20.
25. Riddler SA, Smit E, Cole SR, et al. Impact of HIV infection and HAART on serum lipids in men. JAMA 2003;289:2978 -82.
26. Phillips AN, Carr A, Neuhaus J, et al. Interruption of antiretroviral therapy and risk of cardiovascular disease in persons with HIV-1 infection: exploratory analyses from the SMART trial. Antivir Ther 2008;13:177-87. (Pubitemid 351535369)
27. Hsia SH, Pan D, Berookim P, et al. A population-based, cross-sectional comparison of lipid-related indexes for symptoms of atherosclerotic disease. Am J Cardiol 2006;98:1047-52. (Pubitemid 44486141)